A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 156
- Registration Number
- NCT01237236
- Locations
- 🇳🇱
Novartis Investigative Site, Utrecht, Netherlands
🇺🇸Memorial Sloan Kettering MSKCC (2), New York, New York, United States
🇺🇸Dana Farber Cancer Institute DFCI, Boston, Massachusetts, United States
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1538
- Registration Number
- NCT01235962
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
- Conditions
- Moderate Clostridium Difficile Infection
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 109
- Registration Number
- NCT01232595
- Locations
- 🇨🇦
Novartis Investigative Site, Trois-Rivières, Quebec, Canada
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT01232296
- Locations
- 🇹🇭
Novartis Investigative Site, Songkla, Thailand
12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Long-acting beta2-agonist
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT01232894
- Locations
- 🇮🇱
Novartis Investigative Site, Tel Aviv, Israel
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 214
- Registration Number
- NCT01231594
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- Conditions
- Postmenopausal WomenLocally Advanced Metastatic Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT01231659
- Locations
- 🇮🇱
Novartis Investigative Site, Tel Aviv, Israel
Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria
- Conditions
- Malaria
- Interventions
- Other: Artemether-lumefantrine
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 324
- Registration Number
- NCT01228344
- Locations
- 🇺🇸
Centers for Disease Control and Prevention,GA, Atlanta, Georgia, United States
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 128
- Registration Number
- NCT01227577
- Locations
- 🇺🇸
Hackensack University Medical Center Dept.of HackensackUniv.MedCtr., Hackensack, New Jersey, United States
🇺🇸Advanced Medical Specialties, Miami, Florida, United States
🇺🇸Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT01223898
- Locations
- 🇬🇧
Novartis Investigative Site, Glasgow, United Kingdom